George Kunos, MD, PhD
Inventor, Key Opinion Leader in the Field of CB1
Dr. Kunos received his MD from Semmelweis University (gold medalist) in Budapest, Hungary, and a Ph.D. in pharmacology from McGill University in Montreal, Canada, in Mark Nickerson’s lab.
He was recruited to the NIH as Laboratory Chief at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), where he currently serves as Scientific Director and Chief of the Laboratory of Physiologic Studies.
His laboratory’s work on endocannabinoids led to the development of Inversago’s peripherally-restricted CB1 inverse agonists / antagonists, which in rodent models have potent antiobesity and antidiabetic effects, but are devoid of behavioral side effects.
Rohit N. Kulkarni, MD, PhD
Senior Investigator and Co-Head of the Section on Islet Cell and Regenerative Biology, Joslin Diabetes Center
Dr. Kulkarni is a Senior Investigator and Co-Head of the Section on Islet Cell and Regenerative Biology at the Joslin Diabetes Center, Professor of Medicine and Faculty Member of the Biology and Biomedical Sciences (BBS) Graduate Program at Harvard Medical School and Associate Director of the Diabetes Research Center (DRC).
Dr Kulkarni obtained his MD and PhD degrees from St. John’s Medical College and the Royal Postgraduate Medical School in London.
Dr. Kulkarni is a lead researcher in the field of CB1 receptor biology and its potential for the treatment of T1D.
Christine McCarthy, MD
Associate Partner, Alacrita Consulting and Acting Chief Medical Officer of Inversago Pharma
Dr. McCarthy is a world expert in clinical development for metabolic disease.
Over her career in large pharma, she has been responsible for several late stage clinical development programs including having worldwide responsibility for Sanofi’s Phase III program for Rimonabant, the only approved CB1 obesity / diabetes / dyslipidemia drug.
Dr. McCarthy has also been part of the strategy and innovation team of Sanofi R&D: in this role, she conducted in-depth reviews of numerous projects at different stages of development.
She obtained her MD and specialty degree in rheumatology from St. Antoine Hospital in Paris, France.
Arun J. Sanyal, MD, FASSLD
Professor of Medicine, Physiology and Molecular Pathology, Virginia Commonwealth University School of Medicine
Dr. Arun Sanyal is a Professor of Medicine, Physiology and Molecular Pathology at Virginia Commonwealth University School of Medicine in Richmond, Virginia.
He has over 25 years of experience as a hepatologist and has been advisor to most advanced companies in the field of NASH and hepatology.
Recently, he has helped establish and chair the “Liver Forum” which brings FDA, European Medical Agency, Academia, NIH and industry stakeholders in NASH and hepatic fibrosis together to accelerate therapeutic development in these areas.